News and Trends 18 Sep 2019
Themis Raises €40M for First Phase III Trial of a Chikungunya Vaccine
Vienna-based Themis Biosciences has raised €40M in a Series D round to fund a phase III trial that could lead to the approval of the world’s first vaccine for chikungunya infection. The round, one of the largest seen in Austrian biotech so far, was co-led by two new investors, Farallon Capital and Hadean Ventures. […]